Evidence map›Paper›PMID 38381773›Full record

ArticlePLoS pathogens2024

Antibody profiling and predictive modeling discriminate between Kaposi sarcoma and asymptomatic KSHV infection.

Sydney J Bennett, Dicle Yalcin, Sara R Privatt, Owen Ngalamika, Salum J Lidenge, John T West, Charles Wood

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.7field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. LANA-specific CD4Nature communications · 2025
    Article
  2. Observational
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 3 countries.

Sydney J BennettSchool of Biological Sciences, University of Nebraska-Lincoln, Lincoln, Nebraska, United States of America.
Dicle YalcinDepartment of Interdisciplinary Oncology, Stanley S. Scott Cancer Center, Louisiana State University Health Sciences Center, New Orleans, Louisiana, United States of America.
Sara R PrivattSchool of Biological Sciences, University of Nebraska-Lincoln, Lincoln, Nebraska, United States of America.
Owen NgalamikaDermatology and Venereology Section, University Teaching Hospital, University of Zambia School of Medicine, Lusaka, Zambia.
Salum J LidengeOcean Road Cancer Institute, Dar es Salaam, Tanzania.
John T WestDepartment of Interdisciplinary Oncology, Stanley S. Scott Cancer Center, Louisiana State University Health Sciences Center, New Orleans, Louisiana, United States of America.
Charles WoodSchool of Biological Sciences, University of Nebraska-Lincoln, Lincoln, Nebraska, United States of America.ORCID 0000-0002-4256-1530
University of Nebraska–Lincoln · USLouisiana State University Health Sciences Center New Orleans · USMuhimbili University of Health and Allied Sciences · TZUniversity Teaching Hospital · ZM

Funding

UNMC Structural Biology CoreP20GM103427 · NIGMS · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI James Eudy · 2012 to 2026
$59.2M
UNMC/EPPLEY CANCER CENTER SUPPORT GRANTP30CA036727 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI James Eudy · 1985 to 2026
$55.0M
Seroprevalence of COVID-19 of cancer patients in TanzaniaU54CA190155 · NCI · UNIVERSITY OF NEBRASKA LINCOLN · PI SOLIMAN, AMR, WOOD, CHARLES · 2014 to 2022
$4.5M
Zambia AIDS Malignancies Diagnosis and Pathogenesis Program SupplementU54CA221204 · NCI · UNIVERSITY OF NEBRASKA LINCOLN · PI WOOD, CHARLES · 2017 to 2022
$3.8M
KSHV,HIV and the Kaposi's Sarcoma Tumor NicheR01CA228178 · NCI · UNIVERSITY OF NEBRASKA LINCOLN · PI WEST, JOHN T., WOOD, CHARLES · 2018 to 2024
$2.9M
AIDS Malignancies Training and Research International Program (AMTRIP)D43TW010354 · FIC · UNIVERSITY OF NEBRASKA LINCOLN · PI Chipepo Kankasa, Charles Wood · 2016 to 2026
$2.8M
Biomarkers for Dysbiosis-Related HIV-Associated Cognitive Disorders among Persons Who Inject Drugs in Puerto RicoR01DA047823 · NIDA · UNIVERSITY OF NEBRASKA LINCOLN · PI WOOD, CHARLES · 2019 to 2024
$2.5M
Models for KHSV transmission and its inhibitionR01CA239591 · NCI · UNIVERSITY OF NEBRASKA LINCOLN · PI WEST, JOHN T., WOOD, CHARLES · 2019 to 2024
$2.1M
Tanzania AIDS Malignancies Training and Research Program (TAMTRP)D43TW012277 · FIC · LSU HEALTH SCIENCES CENTER · PI WOOD, CHARLES · 2022 to 2025
$1.4M
Comparative Virology Research Training ProgramT32AI125207 · NIAID · UNIVERSITY OF NEBRASKA LINCOLN · PI WEAVER, ERIC A · 2016 to 2020
$844k
"Plasma and cellular immune biomarkers of Kaposi's sarcoma in HIV-1 suppressed patients"K43TW011418 · FIC · MUHIMBILI UNIVERSITY/ ALLIED HLTH SCIS · PI LIDENGE, SALUM JUMA · 2019 to 2023
$741k
FIC NIH HHS D43 TW010354FIC NIH HHS D43 TW012277FIC NIH HHS K43 TW011418NCI NIH HHS P30 CA036727NCI NIH HHS R01 CA228178NCI NIH HHS R01 CA239591NCI NIH HHS U54 CA190155NCI NIH HHS U54 CA221204NIAID NIH HHS T32 AI125207NIDA NIH HHS R01 DA047823NIGMS NIH HHS P20 GM103427
6 · The paper itself

Abstract

Protein-level immunodominance patterns against Kaposi sarcoma-associated herpesvirus (KSHV), the aetiologic agent of Kaposi sarcoma (KS), have been revealed from serological probing of whole protein arrays, however, the epitopes that underlie these patterns have not been defined. We recently demonstrated the utility of phage display in high-resolution linear epitope mapping of the KSHV latency-associated nuclear antigen (LANA/ORF73). Here, a VirScan phage immunoprecipitation and sequencing approach, employing a library of 1,988 KSHV proteome-derived peptides, was used to quantify the breadth and magnitude of responses of 59 sub-Saharan African KS patients and 22 KSHV-infected asymptomatic individuals (ASY), and ultimately to support an application of machine-learning-based predictive modeling using the peptide-level responses. Comparing anti-KSHV antibody repertoire revealed that magnitude, not breadth, increased in KS. The most targeted epitopes in both KS and ASY were in the immunodominant proteins, notably, K8.129-56 and ORF65140-168, in addition to LANA. Finally, using unbiased machine-learning-based predictive models, reactivity to a subset of 25 discriminative peptides was demonstrated to successfully classify KS patients from asymptomatic individuals. Our study provides the highest resolution mapping of antigenicity across the entire KSHV proteome to date, which is vital to discern mechanisms of viral pathogenesis, to define prognostic biomarkers, and to design effective vaccine and therapeutic strategies. Future studies will investigate the diagnostic, prognostic, and therapeutic potential of the 25 discriminative peptides.

Indexed as

Acquired Immunodeficiency SyndromeHerpesviridae InfectionsHerpesvirus 8, HumanSarcoma, KaposiAntigens, ViralEpitopesHumansNuclear ProteinsPeptidesProteomeAntigens, ViralEpitopesNuclear ProteinsPeptidesProteome

Identifiers

PMID38381773
PMCPMC10911871
OpenAlexW4391993699

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.